Clinical trial
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803 · AstraZeneca, Industry · Active, not recruiting
Key facts
| NCT number | NCT05925803 |
|---|---|
| Title | Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) |
| Official title | A Multicenter, Randomized, Parallel-group, Double-blind,Two-arm Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared With Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive With Systemic Sclerosis |
| Acronym | DAISY |
| Lead sponsor | AstraZeneca, Industry |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Systemic Sclerosis, Scleroderma |
| Intervention type | Combination Product, Drug |
| Interventions | Anifrolumab (blinded), Placebo (blinded), Anifrolumab (unblinded, open label) |
| Enrollment | 314 |
| Start date | Nov 8, 2023 |
| Primary completion | Oct 9, 2026 |
| Completion | Dec 31, 2027 |
| First posted | Jun 29, 2023 |
| Last update posted | Feb 4, 2026 |
| Countries | Austria, Belgium, Canada, China, France, Germany, Hungary, India, Israel, Italy, Japan, Malaysia and 11 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: